Equities analysts expect Sunesis Pharmaceuticals (NASDAQ:SNSS) to post earnings per share (EPS) of ($0.29) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.27). Sunesis Pharmaceuticals posted earnings of ($0.47) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 38.3%. The company is scheduled to report its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.09) to ($0.94). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.16) per share, with EPS estimates ranging from ($1.16) to ($1.15). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Sunesis Pharmaceuticals.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.08.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its stake in Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 64,343 shares in the last quarter. Vatera Holdings LLC purchased a new stake in Sunesis Pharmaceuticals in the 4th quarter worth approximately $673,000. BlackRock Inc. lifted its stake in Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 11,351 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Sunesis Pharmaceuticals by 127.6% in the 3rd quarter. Wells Fargo & Company MN now owns 95,247 shares of the biopharmaceutical company’s stock worth $185,000 after purchasing an additional 53,396 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares in the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.
Shares of SNSS stock traded down $0.02 during trading on Friday, reaching $2.70. 116,774 shares of the company’s stock traded hands, compared to its average volume of 288,270. The stock has a market capitalization of $93.09, a P/E ratio of -1.88 and a beta of 1.81. Sunesis Pharmaceuticals has a 1 year low of $1.82 and a 1 year high of $7.69.
COPYRIGHT VIOLATION WARNING: This article was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://stocknewstimes.com/2018/04/20/sunesis-pharmaceuticals-snss-expected-to-post-earnings-of-0-29-per-share.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.